View in EDS HTML Full Text PDF Full Text

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Saved in:
Bibliographic Details
Title: Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Authors: Hammitt, Laura L1 (AUTHOR), Quinn, Dean2 (AUTHOR), Janczewska, Ewa3 (AUTHOR), Pasquel, Francisco J4 (AUTHOR), Tytus, Richard5 (AUTHOR), Reddy, K Rajender6 (AUTHOR), Abarca, Katia7 (AUTHOR), Khaertynova, Ilsiyar M8 (AUTHOR), Dagan, Ron9 (AUTHOR), McCauley, Jennifer10 (AUTHOR), Cheon, Kyeongmi10 (AUTHOR), Pedley, Alison10 (AUTHOR), Sterling, Tina10 (AUTHOR), Tamms, Gretchen10 (AUTHOR), Musey, Luwy10 (AUTHOR), Buchwald, Ulrike K10 (AUTHOR) ulrike.buchwald@merck.com
Source: Open Forum Infectious Diseases. Mar2022, Vol. 9 Issue 3, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:23288957
DOI:10.1093/ofid/ofab605